The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Daratumumab with IRd in NDMM displays excellent activity
Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, discusses a phase II trial (NCT03012880) designed to examine the safety and efficacy of daratumumab in combination with an all-oral regimen of ixazomib, lenalidomide and modified dose dexamethasone (IRd) in newly diagnosed multiple myeloma (NDMM). Dr Gertz outlines the advantages of this drug regimen and reveals that the combination of daratumumab with IRd is well-tolerated and exhibits excellent activity, including in patients with high-risk genetics. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
